Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Seattle, Washington

CNS medication trials in Seattle, WA

23 CNS medication studies are recruiting participants at sites in Seattle as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Seattle at a glance

  • 23 studies are recruiting at a site in Seattle.
  • By phase: Phase 1 (1), Phase 1/2 (2), Phase 2 (2), Phase 2/3 (1), Phase 3 (15), Phase 4 (1), No phase (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (19), government (2), university, hospital or other (2).
  • By research area: Depression (6), Multiple Sclerosis (5), Migraine (4), Parkinson's Disease (4), Epilepsy (3), ADHD (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Seattle

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Seattle Neuropsychiatric Treatment Center
    Registry record
    NCT06793397 · updated
  2. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    Seattle Neuropsychiatric Treatment Center
    Registry record
    NCT07002034 · updated
  3. Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Puget Sound Health Care System Seattle Division, Seattle, WA
    Registry record
    NCT07226232 · updated
  4. Morphine or Ketamine for Analgesia

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Columbia University
    Study site
    Seattle Children's Hospital
    Registry record
    NCT06835504 · updated
  5. A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07610473 · updated
  6. PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Yale University
    Study site
    Seattle NTC
    Registry record
    NCT06713616 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Seattle, WA on ClinicalTrials.gov.

ADHD studies recruiting in Seattle

  1. Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Puget Sound Health Care System Seattle Division, Seattle, WA
    Registry record
    NCT05776056 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Seattle, WA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Seattle

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Swedish Cancer Institute ( Site 0143)
    Registry record
    NCT06623422 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Fred Hutchinson Cancer Center ( Site 0042)
    Registry record
    NCT06841354 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Fred Hutchinson Cancer Center ( Site 0069)
    Registry record
    NCT06966700 · updated
  4. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Seattle, WA on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Seattle

  1. Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

    • Phase 1
    • Ages 18 to 75
    • All sexes
    Sponsor
    Kite, A Gilead Company
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT07304154 · updated
  2. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated
  3. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    University of Washington MS Clinic
    Registry record
    NCT07225504 · updated
  4. Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    • Phase 1/2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Tr1X, Inc.
    Study site
    Providence Swedish
    Registry record
    NCT07477639 · updated
  5. The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

    • No phase
    • Ages 22 to 60
    • All sexes
    Sponsor
    SetPoint Medical Corporation
    Study site
    UW Medicine Multiple Sclerosis Center-Northwest
    Registry record
    NCT06796504 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Seattle, WA on ClinicalTrials.gov.

Epilepsy studies recruiting in Seattle

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of Washington, Regional Epilepsy Center at Harborview Medical Center
    Registry record
    NCT05667142 · updated
  2. ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

    • Phase 1/2
    • Ages 2 to 12
    • All sexes
    Sponsor
    Ionis Pharmaceuticals, Inc.
    Study site
    Seattle Children's Hospital
    Registry record
    NCT07531745 · updated
  3. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    Seattle Children's Hospital
    Registry record
    NCT04462770 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Seattle, WA on ClinicalTrials.gov.

Migraine studies recruiting in Seattle

  1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Seattle Clinical Research Center
    Registry record
    NCT07645924 · updated
  2. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Seattle Clinical Research Center
    Registry record
    NCT07674654 · updated
  3. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Seattle Children's Hospital · Seattle Children's Hospital Investigational Drug Services
    Registry record
    NCT04649242 · updated
  4. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Seattle Children's Hospital · Seattle Children's Hospital Investigational Drug Services
    Registry record
    NCT04743141 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Seattle, WA on ClinicalTrials.gov.

Ask about studies near Seattle

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Washington

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call